| Company Name: | Zila, Incorporated | | Ticker Symbol: | ZILA | | | WWW Address: | www.zila.com | | CEO: | David R. Bethune | | No. of Employees: | 367 | | Common Issue Type: | CS | | Business Description: | A pharmaceutical company engaged in the prevention, detection and treatment of oral diseases, primarily oral cancer.
|
| | | Industry Information: | HEALTH SERVICES - Medical Instruments & Supplies [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.4415 |  0.0 | 0.01 | 0.95 | 0 | 0.45 | 0.44 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 4.6 | 10.4 | 1.13 | -1.82 | 0.00 | 0.0 | 0.0 | 1.50 - 0.12 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.44 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 4.6 | mil |
| Latest Shares Outstanding | 10.4 | mil |
| Earnings pS (EPS) | -1.82 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 122,781 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 10.1 | mil |
| Float as % of Shares Outstanding | 97.0 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 63.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 1.40 | % |
| Gross Profit Margin | 69.4 | % |
| EBITDA Margin | 4.1 | % |
| Pre-Tax Profit Margin | -82.7 | % |
| Assets Turnover | 1.1 | % |
| Return on Assets (ROA) | -149.7 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -654.7 | % |
| Current Ratio | 0.7 | |
| Leverage Ratio (Assets/Equity) | 5.5 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 2.65 | |
| LT Debt/Total Capital | 10.0 | % |
| Working Capital pS | -0.50 | $ |
| Cash pS | 0.29 | $ |
| Book-Value pS | 0.37 | $ |
| Tangible Book-Value pS | -0.06 | $ |
| Cash Flow pS | -2.45 | $ |
| Free Cash Flow pS | -0.02 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.19 | |
| Price/Tangible Book Ratio | -7.37 | |
| Price/Cash Flow | -0.2 | |
| Price/Free Cash Flow | -22.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 100 | 211 | 0 |
| 4 Weeks | 0.46 | 0.44 | 0.44 | 0.0 | 97 | 252 | 3,781 |
| 13 Weeks | 0.47 | 0.36 | 0.36 | 22.2 | 105 | 647 | 38,147 |
| 26 Weeks | 0.80 | 0.15 | 0.20 | 120.0 | 169 | 927 | 113,035 |
| 52 Weeks | 1.50 | 0.12 | 1.24 | -64.5 | 40 | 927 | 228,937 |
| YTD | 0.85 | 0.12 | - | 57.1 | 133 | 1,092 | 197,596 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.45 | 0.44 | 0.43 | 0.34 | 0.33 | 1.13 | 1.04 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -4.31 | 11.8 | 12.92 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 22.54 | NA | 9.09 |
| R&D | -28.98 | NA | -53.20 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -19.8 | -24.7 | 56.5 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -1.28 | 0.35 | -0.21 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 13.02 |
| Current Ratio | 1.8 |
| Quick Ratio (Acid Test) | 1.2 |
| Liquidity Ratio (Cash) | 0.55 |
| Receivables Turnover | 9.5 |
| Average Collection Period | 38 |
| Working Capital/Equity | 20.0 |
| Working Capital pS | 0.66 |
| Cash-Flow pS | -0.98 |
| Free Cash-Flow pS | -0.88 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -0.07 |
| Financial Leverage Ratio (Assets/Equity) | 1.5 |
| Debt Ratio | 33.9 |
| Total Debt/Equity (Gearing Ratio) | 0.28 |
| LT Debt/Equity | 0.27 |
| LT Debt/Capital Invested | 21.2 |
| LT Debt/Total Liabilities | 52.5 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 7.65 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.36 |
| Tobin's Q Ratio | 0.09 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -2.78 |
| Enterprise Value (EV)/Free Cash Flow | -5.22 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -7.37 |
| Price/Book Ratio - LTM | 1.19 |
| Price/Cash Flow Ratio | -0.2 |
| Price/Free Cash Flow Ratio - LTM | -22.1 |
| Price/Sales Ratio | 0.12 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.90 |
| Current Liabilities pS | 0.82 |
| Tangible Book Value pS - LTM | -0.06 |
| Book Value pS - LTM | 0.37 |
| Capital Invested pS | 4.05 |
| Cash pS - LTM | 0.29 |
| Cash Flow pS - LTM | -2.45 |
| Free Cash Flow pS - LTM | -0.02 |
| Earnings pS (EPS) | -1.82 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -19.42 |
| Free Cash Flow Margin 5YEAR AVG | -62.00 |
| Net Profit Margin | -36.3 |
| Net Profit Margin - 5YEAR AVRG. | -31.7 |
| Equity Productivity | 1.37 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 1.07 |
| Return on Capital Invested (ROCI) | -38.8 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -26.9 |
| Assets Productivity | 0.80 |
| Return on Assets (ROA) | -32.5 |
| Return on Assets (ROA) - 5YEAR AVRG. | -20.8 |
| Gross Profit Margin | 69.4 |
| Gross Profit Margin - 5YEAR AVRG. | 66.8 |
| EBITDA Margin - LTM | 4.1 |
| EBIT Margin - LTM | -72.9 |
| Pre-Tax Profit Margin | -35.8 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -43.9 |
| Effective Tax Rate | 0.1 |
| Effective Tax Rate - 5YEAR AVRG. | 4.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 130 |
| Revenue per Employee | 122,781 |
| Net Income per Employee | -44,627 |
| Average Collection Period | 42 |
| Receivables Turnover | 9.5 |
| Day's Inventory Turnover Ratio | 88 |
| Inventory Turnover | 4.1 |
| Inventory/Sales | 6.9 |
| Accounts Payble/Sales | 8.53 |
| Assets/Revenue | 1.25 |
| Net Working Capital Turnover | 6.87 |
| Fixed Assets Turnover | 1.26 |
| Total Assets Turnover | 0.8 |
| Revenue per $ Cash | 10.10 |
| Revenue per $ Plant | 8.47 |
| Revenue per $ Common Equity | 1.37 |
| Revenue per $ Capital Invested | 1.07 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 76.3 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 76.2 |
| Research & Devlopment (R&D) as % of Revenue | 5.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 5.4 |
|
|  
|
| |
 |  |